SCHEMBL1923720

SCHEMBL1923720

Cc1ccc2c(=O)c(-c3ccccc3)cn(CC(=O)N3C(C)C=CC3C)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP10 Q14694 4/20 0.40
PTGDR2 Q9Y5Y4 3/20 0.36
MARK4 Q96L34 1/20 0.35
MAPT P10636 3/20 0.34
PKM P14618 1/20 0.34
HTT P42858 1/20 0.34
GRIN2B Q13224 2/20 0.34
TP53 P04637 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
S1PR1 P21453 1/20 0.34
NR1I2 O75469 1/20 0.33
EGFR P00533 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
TBXA2R P21731 1/20 0.33
PTGS2 P35354 1/20 0.33
OPRD1 P41143 1/20 0.33
PDE4D Q08499 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1923526 0.88 MAPT (0.34) PTGDR2MAPTPKMALDH1A1GAA
SCHEMBL1923643 0.88 USP10 (0.39) USP10MARK4MAPTTP53ALDH1A1
SCHEMBL1924088 0.84 PTGDR2 (0.47) USP10PTGDR2MARK4MAPTALDH1A1
SCHEMBL1924841 0.82 ALDH1A1 (0.53) USP10GRIN2BALDH1A1SMN1; SMN2
SCHEMBL1923580 0.82 MAPT (0.50) USP10MAPTHTTGRIN2BTP53
SCHEMBL1923600 0.82 SMN1; SMN2 (0.46) USP10HTTGRIN2BTP53ALDH1A1
SCHEMBL1923726 0.81 MAPT (0.51) USP10MAPTHTTGRIN2BTP53
SCHEMBL1923633 0.81 USP10 (0.46) USP10MAPTHTTGRIN2BTP53
SCHEMBL1924745 0.80 EGFR (0.47) USP10PTGDR2MAPTHTTALDH1A1
SCHEMBL1923300 0.80 USP10 (0.49) USP10MAPTHTTGRIN2BTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 EP claimed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 US claimed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 EP claimed
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 EP disclosed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 US disclosed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 EP disclosed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 WO disclosed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS GABRA1, GABRA4, GABRA2 USP10 3340/4885PTGDR2 546/4885MARK4 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.